MOTS-C
10 mg / 40 mg
Mitochondrial-encoded peptide studied for its role in energy homeostasis and metabolic flexibility through the AMPK pathway. Research describes effects on glucose and fatty-acid utilization.
- Studied for its effect on glucose metabolism
- Investigated for endurance capacity
- Studied for its effect on visceral adipose tissue
- Investigated in aging-related research models
Scientific context
Origin, mechanism, and research
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA, discovered in 2015 by Changhan Lee and Pinchas Cohen (University of Southern California) and published in Cell Metabolism — the first to show that a mitochondrial sequence can act as a systemic hormonal signal. It is not an approved drug. Available evidence is mostly preclinical (mice, cell cultures), where MOTS-c activates AMPK, stimulating mitochondrial biogenesis, lipid oxidation, and glucose uptake in skeletal muscle. In 2026 it began its first human clinical trial (phase 2a, prediabetes/overweight), results not yet published.
Information for educational and informational purposes, based on public sources; it does not constitute medical advice. Product for laboratory research use only — not for human consumption.
